Expand ASND Menu
ASND MENU

ASND Latest Press Releases

-- April 25, 2024 --

Ascendis Pharma to Report First Quarter 2024 Financial Results and Provide Business Update on May 2, 2024 Globe Newswire 4:46 PM

-- April 24, 2024 --

United Kingdom's MHRA Approves YORVIPATH (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism Globe Newswire 8:30 AM

-- March 4, 2024 --

Ascendis Pharma to Participate in the Leerink Partners Global Biopharma Conference 2024 Globe Newswire 8:30 AM

-- February 7, 2024 --

Ascendis Pharma Reports Fourth Quarter and Full Year 2023 Results Globe Newswire 4:01 PM
Ascendis Pharma to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference Globe Newswire 8:30 AM

-- January 31, 2024 --

Ascendis Pharma to Report Full Year 2023 Financial Results and Provide Business Update on February 7, 2024 Globe Newswire 4:15 PM
Ascendis Pharma Launches 2nd TransCon Product: YORVIPATH Now Available in Germany and Austria for Adults with Chronic Hypoparathyroidism Globe Newswire 4:01 PM

-- January 29, 2024 --

New Company Eyconis Formed to Develop Ascendis Pharma Ophthalmology Assets with $150 Million Commitment from External Investors Globe Newswire 8:30 AM

-- January 8, 2024 --

Er-Kim Announces Exclusive Distribution Agreement with Ascendis Pharma A/S to Commercialize 3 Endocrinology Disease Treatments Across Central & Eastern Europe and Turkey Globe Newswire 6:01 PM
Vector Pharma FZCO Announce Exclusive Distribution Agreement with Ascendis Pharma A/S for Skytrofa (lonapegsomatropin) and Yorvipath (palopegteriparatide) in Gulf Cooperation Council Countries Globe Newswire 8:20 AM

-- January 7, 2024 --

Ascendis Pharma Introduces Vision 2030 Globe Newswire 5:45 PM
Specialised Therapeutics signs exclusive agreement with Ascendis Pharma A/S for distribution and commercialisation of three endocrinology therapies in Australia and select South-East Asia countries PRNewswire 2:00 PM

-- December 28, 2023 --

Ascendis Pharma to Participate in the 42nd Annual J.P. Morgan Healthcare Conference Globe Newswire 4:15 PM

-- December 20, 2023 --

Significant Health and Quality of Life Improvements Achieved in Children with Achondroplasia Treated for One Year with TransCon CNP (Navepegritide) at 100 g/kg/week Globe Newswire 8:30 AM

-- December 19, 2023 --

TransCon hGH (lonapegsomatropin) Achieved Statistically Superior Outcomes Compared to Placebo in Phase 3 foresiGHt Trial of Adults with Growth Hormone Deficiency Globe Newswire 8:30 AM

-- December 11, 2023 --

FDA Accepts for Review Resubmitted NDA for TransCon PTH (Palopegteriparatide) in Adult Patients with Hypoparathyroidism Globe Newswire 8:30 AM

-- November 29, 2023 --

Ascendis Pharma Announces Strategic Partnership with Teijin Limited in Japan Globe Newswire 4:30 AM